Your session is about to expire
← Back to Search
Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients
N/A
Waitlist Available
Research Sponsored by Intermountain Health Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 to 180 days
Awards & highlights
No Placebo-Only Group
Summary
A systematic review and meta analysis will be performed of risk assessment models for Venous thromboembolism ("VTE" including pulmonary embolism "PE" and deep venous thrombosis "DVT")in hospitalized medical patients. The goal of this study is to evaluate whether the incidence of VTE is lower in patients that are evaluated with a risk assessment model and treated with thromboprophylaxis for their assigned level of risk.
Eligible Conditions
- Venous Thromboembolism
- Deep Vein Thrombosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 to 180 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 to 180 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
VTE
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hospitalized Medical PatientsExperimental Treatment1 Intervention
All hospitalized medical adult patients
Find a Location
Who is running the clinical trial?
Intermountain Health Care, Inc.Lead Sponsor
139 Previous Clinical Trials
1,963,960 Total Patients Enrolled
3 Trials studying Venous Thromboembolism
3,252 Patients Enrolled for Venous Thromboembolism
Scott C Woller, MDStudy DirectorIntermountain Health Care, Inc.
1 Previous Clinical Trials
48 Total Patients Enrolled